Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
The aim of the biotech company is to “transform healthcare by providing comprehensive information on patient predisposition to disease, disease prevention and personalized intervention and treatments."
Cynthia Rudin, PhD, is a highly regarded computer scientist who’s been eyeing the advance of artificial intelligence into society with equal parts enthusiasm and concern.
“Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate technology with the scale and strength of Pfizer’s capabilities and expertise," says Pfizer Chairman and CEO Albert Bourla, PhD.
By now it’s a difficult-to-dispute likelihood: AI won’t replace doctors making diagnoses, but doctors who use AI will displace doctors who don’t use AI. The hypothesis gets a fresh airing out from the vantage point of the general public.
